Jon C Mills1, Jeffrey S Harman2, Robert L Cook3, Nicole M Marlow4, Christopher A Harle5, R Paul Duncan6, Angela M Bengtson7, Brian W Pence8. 1. University of North Carolina, Chapel Hill, Department of Epidemiology, United States. Electronic address: jon_mills@med.ufl.edu. 2. Florida State University, Department of Behavioral Sciences and Social Medicine, United States. Electronic address: jeffrey.harman@med.fsu.edu. 3. University of Florida, Department of Epidemiology and Medicine, United States. Electronic address: cookrl@ufl.edu. 4. University of Florida, Department of Health Services Research, Management and Policy, United States. Electronic address: marlownm@phhp.ufl.edu. 5. Indiana University, Indianapolis, Department of Health Policy and Management, United States. Electronic address: charle@iu.edu. 6. University of Florida, Department of Health Services Research, Management and Policy, United States. Electronic address: pduncan@ufl.edu. 7. University of North Carolina, Chapel Hill, Department of Epidemiology, United States. Electronic address: abengtso@live.unc.edu. 8. University of North Carolina, Chapel Hill, Department of Epidemiology, United States. Electronic address: bpence@unc.edu.
Abstract
BACKGROUND: Depression is the most common psychiatric comorbidity among people living with HIV/AIDS (PLWHA). Little is known about the comparative effectiveness between different types of antidepressants used to treat depression in this population. We compared the effectiveness of dual-action and single-action antidepressants in PLWHA for achieving remission from depression. METHODS: We used data from the Centers for AIDS Research Network of Integrated Clinic Systems to identify 1175 new user dual-action or single-action antidepressant treatment episodes occurring from 2005 to 2014 for PLWHA diagnosed with depression. The primary outcome was remission from depression defined as a Patient Health Questionnaire-9 (PHQ-9) score <5. Mean difference in PHQ-9 depressive symptom severity was a secondary outcome. The main approach was an intent-to-treat (ITT) evaluation complemented with a per protocol (PP) sensitivity analysis. Generalized linear models were fitted to estimate treatment effects. RESULTS: In ITT analysis, 32% of the episodes ended in remission for both dual-action and single-action antidepressants. The odds ratio (OR) of remission was 1.02 (95%CI=0.63,1.67). In PP analysis, 40% of dual-action episodes ended in remission compared to 32% in single-action episodes. Dual-action episodes had 1.33 times the odds of remission (95%CI=0.55,3.21), however the result was not statistically significant. Non-significant differences were also observed for depressive symptom severity. LIMITATIONS: Missing data was common but was addressed with inverse probability weights. CONCLUSIONS: Results suggest that single-action and dual-action antidepressants are equally effective in PLWHA. Remission was uncommon highlighting the need to identify health service delivery strategies that aid HIV providers in achieving full remission of their patients' depression.
BACKGROUND:Depression is the most common psychiatric comorbidity among people living with HIV/AIDS (PLWHA). Little is known about the comparative effectiveness between different types of antidepressants used to treat depression in this population. We compared the effectiveness of dual-action and single-action antidepressants in PLWHA for achieving remission from depression. METHODS: We used data from the Centers for AIDS Research Network of Integrated Clinic Systems to identify 1175 new user dual-action or single-action antidepressant treatment episodes occurring from 2005 to 2014 for PLWHA diagnosed with depression. The primary outcome was remission from depression defined as a Patient Health Questionnaire-9 (PHQ-9) score <5. Mean difference in PHQ-9 depressive symptom severity was a secondary outcome. The main approach was an intent-to-treat (ITT) evaluation complemented with a per protocol (PP) sensitivity analysis. Generalized linear models were fitted to estimate treatment effects. RESULTS: In ITT analysis, 32% of the episodes ended in remission for both dual-action and single-action antidepressants. The odds ratio (OR) of remission was 1.02 (95%CI=0.63,1.67). In PP analysis, 40% of dual-action episodes ended in remission compared to 32% in single-action episodes. Dual-action episodes had 1.33 times the odds of remission (95%CI=0.55,3.21), however the result was not statistically significant. Non-significant differences were also observed for depressive symptom severity. LIMITATIONS: Missing data was common but was addressed with inverse probability weights. CONCLUSIONS: Results suggest that single-action and dual-action antidepressants are equally effective in PLWHA. Remission was uncommon highlighting the need to identify health service delivery strategies that aid HIV providers in achieving full remission of their patients' depression.
Authors: Julie L Adams; Bradley N Gaynes; Teena McGuinness; Riddhi Modi; James Willig; Brian W Pence Journal: AIDS Patient Care STDS Date: 2012-11 Impact factor: 5.078
Authors: Jon C Mills; Jeffrey S Harman; Robert L Cook; Nicole M Marlow; Christopher A Harle; R Paul Duncan; Bradley N Gaynes; Brian W Pence Journal: AIDS Date: 2017-11-28 Impact factor: 4.177